Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report

On November 7th and 8th, 2022, The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), The Coalition for Epidemic Preparedness Innovation (CEPI), The Bill & Melinda Gates Foundation (BMGF), The Biomedical Advanced Research and Developme...

Descripción completa

Detalles Bibliográficos
Autores principales: Knisely, Jane M., Buyon, Lucas E., Mandt, Rebecca, Farkas, Rebecca, Balasingam, Shobana, Bok, Karin, Buchholz, Ursula J., D’Souza, M. Patricia, Gordon, Jennifer L., King, Deborah F. L., Le, Tung T., Leitner, Wolfgang W., Seder, Robert A., Togias, Alkis, Tollefsen, Stig, Vaughn, David W., Wolfe, Daniel N., Taylor, Kimberly L., Fauci, Anthony S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Meeting Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091310/
https://www.ncbi.nlm.nih.gov/pubmed/37045860
http://dx.doi.org/10.1038/s41541-023-00654-6
Descripción
Sumario:On November 7th and 8th, 2022, The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), The Coalition for Epidemic Preparedness Innovation (CEPI), The Bill & Melinda Gates Foundation (BMGF), The Biomedical Advanced Research and Development Authority (BARDA), and the Wellcome Trust hosted a virtual workshop entitled “Mucosal Vaccines for SARS-CoV-2: Scientific Gaps and Opportunities.” During the workshop, researchers and vaccine developers from around the world discussed the potential of mucosal vaccines to block SARS-CoV-2 transmission and reviewed the status of SARS-CoV-2 mucosal vaccine research. Here, we summarize key challenges and opportunities in basic, translational, and clinical research that were highlighted during the meeting. We also provide recommendations to advance the field and accelerate the development of mucosal vaccines for SARS-CoV-2.

Ejemplares similares